Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2018 16:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces Completion of $11.25 Million Public Offering

WALTHAM, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
April 13, 2018 07:00 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces $11.25 Million Public Offering

WALTHAM, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
April 11, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Issued New Patent for Iontophoretic Contact Lens Technology

WALTHAM, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
April 09, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
April 06, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

WALTHAM, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), today announced completion of patient enrollment for the pivotal Phase 3...
March 09, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharma To Participate At The 30TH Annual ROTH Conference

WALTHAM, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
March 08, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

WALTHAM, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
March 02, 2018 16:28 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update

WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
February 07, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate to Present at the 2018 BIO CEO & Investor Conference

WALTHAM, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
February 05, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right